Not a single one of these events would “drive value” this year. The only thing that would “drive value” this year would be a big pharma collaboration (not at all likely) or final data from a large Phase 3 trial (not this year and probably not next year), or a regulatory approval (not in the cards for at least a few years).
The truth is, there is nothing on the horizon this year that would propel the stock higher. There are a great many investors who bought AVXL at much higher prices. Following a great year in the stock market, many investors will be looking to offset capital gains by selling their losers.
With no market-moving news on the horizon, investors with losses will be selling. With tax-loss selling season approaching and no meaningful news, AVXL will be under pressure between now and the end of the year.
Market Data 
Markets 
AI
